Molecular Probes

Clinical Trial Imaging Market worth $1.9 billion | MarketsandMarkets

Retrieved on: 
Freitag, August 18, 2023
Well, ICON PLC, Subjectivity, ICON, Incidence, Magnetic resonance imaging, Translational research, Conditional sentence, Digital, Health, Neurology, Clinical, Software, CT, CVS, Infection, HIV disease progression rates, Molecular Probes, Safety, Endocrinology, Leo Pharma, Echocardiography, Biotechnology, Cancer, Radiopharmaceutical, IXICO, Drug, Partnership, Drug development, Clinical trial, PET, We Are One (global collaboration song), Cardiology, Pharmaceutical industry, Medical imaging, Medical device

The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022

Key Points: 
  • The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022
    Based on product, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2022
    Based on therapeutic area, the clinical trial imaging market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area.
  • Clinical Trial Imaging Market Dynamics:
    Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
    The major players operating in this market are ICON plc.

Clinical Trial Imaging Market worth $1.9 billion | MarketsandMarkets

Retrieved on: 
Freitag, August 18, 2023
Well, ICON PLC, Subjectivity, ICON, Incidence, Magnetic resonance imaging, Translational research, Conditional sentence, Digital, Health, Neurology, Clinical, Software, CT, CVS, Infection, HIV disease progression rates, Molecular Probes, Safety, Endocrinology, Leo Pharma, Echocardiography, Biotechnology, Cancer, Radiopharmaceutical, IXICO, Drug, Partnership, Drug development, Clinical trial, PET, We Are One (global collaboration song), Cardiology, Pharmaceutical industry, Medical imaging, Medical device

The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022

Key Points: 
  • The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022
    Based on product, the clinical trial imaging market is segmented into services and software.
  • The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities.
  • The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2022
    Based on therapeutic area, the clinical trial imaging market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area.
  • Clinical Trial Imaging Market Dynamics:
    Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
    The major players operating in this market are ICON plc.

Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use

Retrieved on: 
Montag, Juni 12, 2023
Research, Technology, Infectious Diseases, Other Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, EUA, UDM, Hair, Infection, Bachelor, BMB, Allergy, Workflow, RPP, Culture, SARS-CoV-2, Software, Pneumocystis jirovecii, COVID-19, Eye, Aspergillus, Histoplasma capsulatum, CE marking, PCR, Nomenclature codes, Immunochemistry, Emergency Use Authorization, Federal Food, Drug, and Cosmetic Act, Panel, Coccidioides, RSV, RUO, Patient, Laboratory, Autoimmune disease, Molecular Probes, IVD, Growth, GPP, Immunodeficiency, Diagnosis, FDA, Mucor, Virus, Vaccine, Rhizopus, Applied Spectral Imaging, Rhizomucor, Fusarium, Cunninghamella, Cryptococcus

The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.

Key Points: 
  • The Fungal Panel Assay was developed to detect the most common agents of invasive fungal infections (IFIs) particularly in lower respiratory samples.
  • Applied BioCode’s Fungal Panel is intended for research use only and may be used in infectious disease research or pharmaceutical development.
  • “Applied BioCode is thrilled to announce our first release of an RUO panel under our new product strategy.
  • Applied BioCode, Inc. has also been granted an Emergency Use Authorization (EUA) from the U.S. FDA for its BioCode® SARS-CoV-2 Flu Plus Assay ⱡ, BioCode® SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*.

Applied BioCode Announces Distribution Agreement with Medline Industries

Retrieved on: 
Montag, Mai 8, 2023
Infectious Diseases, Biotechnology, Hospitals, Health, EUA, Hair, Bachelor, BMB, Allergy, RPP, Medline Industries, SARS-CoV-2, COVID-19, Infection, CE marking, Applied Food Technologies, MEDLINE, Nomenclature codes, Lower respiratory tract infection, Immunochemistry, Emergency Use Authorization, Federal Food, Drug, and Cosmetic Act, Hospital, RSV, Analyte-specific reagent, Laboratory, Autoimmune disease, Molecular Probes, LDT, IVD, Diagnosis, GPP, FDA, Virus, Pharmaceutical industry, Vaccine

Applied BioCode today announced an agreement with Medline Industries, a leading manufacturer and distributor of healthcare products, to distribute the MDx-3000 System and its comprehensive menu.

Key Points: 
  • Applied BioCode today announced an agreement with Medline Industries, a leading manufacturer and distributor of healthcare products, to distribute the MDx-3000 System and its comprehensive menu.
  • Under the terms of the distribution agreement, Medline will offer the MDx-3000 System to clinical laboratory customers across the U.S.
    “Applied BioCode is thrilled to partner with Medline Industries, and we look forward to continuing our expansion into hospitals and reference laboratories in the U.S.,” said Chris Bernard, CEO of Applied BioCode.
  • For more information on the Applied BioCode’s platform and products, visit: https://apbiocode.com/products.htm
    Applied BioCode is an IVD manufacturer that designs, develops, and commercializes multiplex testing products.
  • Applied BioCode, Inc. has also been granted an Emergency Use Authorization (EUA) from the U.S. FDA for its BioCode® SARS-CoV-2 Flu Plus Assay ⱡ, BioCode® SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*.

Applied BioCode Announces 2022 Q4 and Full year Revenue

Retrieved on: 
Montag, Februar 27, 2023
FDA, Chemicals, Plastics, Manufacturing, Technology, Nanotechnology, Public Relations, Investor Relations, Other Travel, Communications, General Health, Travel, Other Manufacturing, Other Technology, Science, Other Science, Research, Health, Bacteria, CE marking, Emergency Use Authorization, Autoimmune disease, RPP, Overalls, Diagnosis, Fungus, IVD, RSV, Federal Food, Drug, and Cosmetic Act, Microbiology, Bachelor, Parasitism, Laboratory, Virus, Patient, Nomenclature codes, RUO, Growth, Immunochemistry, BMB, Yoy, Molecular Probes, Syndromic testing, Allergy, EUA, GPP, Hair, Infection, COVID-19, COVID, SARS-CoV-2, Video game, Vaccine

Applied BioCode announced today its 2022 revenue $13MM, which marks 13% growth year over year, hitting the company’s historic high.

Key Points: 
  • Applied BioCode announced today its 2022 revenue $13MM, which marks 13% growth year over year, hitting the company’s historic high.
  • Q4 revenue was just shy of $4MM representing 9% growth quarter over quarter.
  • Applied BioCode, Inc. has also been granted an Emergency Use Authorization (EUA) from the U.S. FDA for its BioCode® CoV-2 Flu Plus Assay ⱡ, BioCode® SARS-CoV-2 Assay*, and an additional EUA for Pooled COVID-19 Testing*.
  • Applied BioCode also partners with a variety of diagnostic companies with applications that include the infectious disease, autoimmune disease, allergy, gut microbiome, and veterinary markets.

Applied BioCode Appoints Industry Veteran Chris Bernard as Chief Executive Officer

Retrieved on: 
Donnerstag, März 24, 2022
Research, General Health, Medical Devices, Technology, Infectious Diseases, Science, Nanotechnology, Veterinary, Biotechnology, Other Technology, Other Science, Health, Virus, Leadership, Federal Food, Drug, and Cosmetic Act, Diagnosis, Growth, IVD, PCR, Board, EUA, Molecular Probes, RPP, Hologic, CEO, Severe acute respiratory syndrome coronavirus 2, Laboratory, Autoimmune disease, Immunochemistry, Technology, Infection, GPP, Director, Knowledge, Emergency Use Authorization, Workflow, COVID-19, Allergy, Hair, Nomenclature codes, BMB, Â, Solution, RSV, CE marking, Applied Food Technologies, FDA, Medical degree, Management, Vaccine, Medical device

Applied BioCode announced today that Chris Bernard has been appointed as their new Chief Executive Officer (CEO).

Key Points: 
  • Applied BioCode announced today that Chris Bernard has been appointed as their new Chief Executive Officer (CEO).
  • Mr. Bernard joins as Applied BioCode continues to expand its US commercial footprint and explores US & global expansion and new opportunities for their technology.
  • Chris Bernard brings 27 years of strong commercial, operational, and R&D leadership experience in diagnostics and medical devices to Applied BioCode.
  • The Applied BioCode team has developed a really innovative, multiplex PCR-based technology and the platform is uniquely positioned in the marketplace, said Mr. Bernard.

Applied BioCode Announces Exclusive Partner Distribution Agreement with Hardy Diagnostics, Further Broadens Reach of BioCode® MDx-3000 System into Hospitals and Reference Laboratories in the United States

Retrieved on: 
Montag, März 14, 2022
Manufacturing, Women, Men, Consumer, Other Travel, Other Communications, Travel, Marketing, Small Business, Communications, Other Automotive, Telecommunications, Software, Internet, Science, Finance, Data Management, Consumer Electronics, Banking, Automotive, Technology, Accounting, Professional Services, Vacation, Mining, Minerals, Semiconductor, Agriculture, Natural Resources, Utilities, Research, Other Manufacturing, Nanotechnology, Audio, Video, Energy, Engineering, Chemicals, Plastics, Federal Food, Drug, and Cosmetic Act, Virus, Laboratory, Hardy, Company, Analyte-specific reagent, Hardy Diagnostics, Allergy, FDA, RSV, EUA, RPP, LDT, Infection, CE marking, GPP, Respiratory tract, ASRS, Hospital, Nomenclature codes, Immunochemistry, IVD, Applied Spectral Imaging, Emergency Use Authorization, Hair, BMB, Autoimmune disease, COVID-19, Microbiology, Molecular Probes, Severe acute respiratory syndrome coronavirus 2, Medical degree, Diagnosis, Medical device, Vaccine

Under the terms of the exclusive agreement, Hardy Diagnostics will begin offering the MDx-3000 System to clinical laboratory customers in the United States.

Key Points: 
  • Under the terms of the exclusive agreement, Hardy Diagnostics will begin offering the MDx-3000 System to clinical laboratory customers in the United States.
  • Applied BioCode is thrilled to partner with Hardy Diagnostics, and we look forward to working closely with the Hardy team to expand our reach to hospitals and reference laboratories in the US, said Winston Ho, President of Applied BioCode.
  • Jay Hardy, Chief Executive Officer of Hardy Diagnostics, said, "We are very excited to add the Applied BioCode MDx-3000 molecular platform to our lineup of instruments to streamline the processes for microbiologists."
  • Hardy adds, "Our Company prides itself on offering our laboratory partners innovative solutions to detect and diagnose disease.

Hardy Diagnostics Now Offers the BioCode® MDx-3000

Retrieved on: 
Montag, März 14, 2022
Federal Food, Drug, and Cosmetic Act, Gram, Partnership, NL63, Laboratory, RPP, OC43, STEC, Campylobacter, Hair, BMB, Emergency Use Authorization, Severe acute respiratory syndrome coronavirus 2, Bacteria, Stanford University v. Roche Molecular Systems, Inc., Hardy, Escherichia coli, Hardy Diagnostics, Allergy, FDA, EIEC, EUA, Infection, EAEC, GLOBE, Hematology, Autoimmune disease, LIS, Microbiology, ETEC, PCR, Automation, 1993 Jack in the Box E. coli outbreak, RSV, Vibrio parahaemolyticus, Culture, GPP, Immunochemistry, Nomenclature codes, IVD, Fungus, Medical degree, Molecular Probes, Yersinia enterocolitica, Virus, COVID, HKU1, Laboratory information management system, CE marking, Hospital, Technology, COVID-19, Diagnosis, Vaccine, Medical device, Coronavirus

"Applied BioCode is thrilled to partner with Hardy Diagnostics," said Winston Ho, President of Applied BioCode.

Key Points: 
  • "Applied BioCode is thrilled to partner with Hardy Diagnostics," said Winston Ho, President of Applied BioCode.
  • "We look forward to working with the Hardy Diagnostics team to expand our reach in hospitals and reference laboratories in the US."
  • Hardy Diagnostics is an FDA-licensed manufacturer of medical devices for microbiology testing with an ISO 13485 certified Quality Management System.
  • Hardy Diagnostics distributes more than 13,000 products, services more than 10,000 laboratories and exports to more than 80 foreign distributors.

Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology

Retrieved on: 
Freitag, Januar 14, 2022
Triple-negative breast cancer, Patient, Technology, News, Molecular Probes, CSO, Antibody, Proteome, CEO, Proteomics, Mass spectrometry, Pain, Epitope, USPTO, Therapy, Pain management, Mab, Environment, Cancer, Patent, TRPV1, KRAS, Vaccine, Fine chemical, Science Advances

The grant of this patent provides further recognition of the high quality of the innovation being carried out by Oblique Therapeutics' team.

Key Points: 
  • The grant of this patent provides further recognition of the high quality of the innovation being carried out by Oblique Therapeutics' team.
  • Owe Orwar, Ph.D., Professor, Founder and CEO of Oblique Therapeutics says:
    "We are absolutely thrilled by the news from USPTO.
  • We are today developing a number of programs out of the AbiProt platform with a focus on pain and aggressive cancer.
  • Oblique Therapeutics is applying this technology for discovery of a new generation of selective antibody therapeutics targeting cancer and pain.

Oblique Therapeutics is pleased to announce that the United States Patent and Trademark Office has granted a patent for its innovative AbiProt® technology

Retrieved on: 
Freitag, Januar 14, 2022
Triple-negative breast cancer, Patient, Technology, News, Molecular Probes, CSO, Antibody, Proteome, CEO, Proteomics, Mass spectrometry, Pain, Epitope, USPTO, Therapy, Pain management, Mab, Environment, Cancer, Patent, TRPV1, KRAS, Vaccine, Fine chemical, Science Advances

The grant of this patent provides further recognition of the high quality of the innovation being carried out by Oblique Therapeutics' team.

Key Points: 
  • The grant of this patent provides further recognition of the high quality of the innovation being carried out by Oblique Therapeutics' team.
  • Owe Orwar, Ph.D., Professor, Founder and CEO of Oblique Therapeutics says:
    "We are absolutely thrilled by the news from USPTO.
  • We are today developing a number of programs out of the AbiProt platform with a focus on pain and aggressive cancer.
  • Oblique Therapeutics is applying this technology for discovery of a new generation of selective antibody therapeutics targeting cancer and pain.